Scientific publisher Nature Publishing Group (NPG), UK, and BioCentury Publications, Inc., US, have announced the inaugural edition of SciBX: Science-Business eXchange, a weekly publication. Leveraging the business intelligence of BioCentury and the scientific acumen of NPG, SciBX seeks to identify and evaluate new developments in science and technology that have commercial and investment potential within the biotechnology and pharmaceutical arena.
The inaugural issue describes how University of North Carolina research may point the way for Alexion Pharmaceuticals, Inc. and Trillium Therapeutics Inc. to extend their antibodies from blood cancers into solid tumours and provide new competition for advanced melanoma compounds in the clinic. SciBX's science-business approach is exemplified by a pathway map showing the players and clinical programmes affected by this new finding.
The publication will evaluate hundreds of high impact peer-reviewed scientific articles every week and pick the most commercially relevant findings that merit deeper analysis. Such a multidisciplinary approach is expected to provide scientific context, identify potential commercial impact and describe the next steps required to translate the newest developments in the lab into innovative healthcare solutions.
The Inaugural Edition is available without charge to readers through the SciBX website at www.scibx.com.
More News in this Theme
